Clinical Trials
80 trialsPan Tumor Rollover Study
Bristol-Myers Squibb
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
KANDLELIT-001
Merck Sharp & Dohme LLC
MK-3475-01G
Merck Sharp & Dohme LLC
MK-3475-01E
Merck Sharp & Dohme LLC
KANDLELIT-007
Merck Sharp & Dohme LLC
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Inhibrx Biosciences, Inc
NeoCOAST-2
AstraZeneca
TroFuse-019
Merck Sharp & Dohme LLC
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
AstraZeneca
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
BioNTech SE
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
RELATIVITY1093
Bristol-Myers Squibb
TeLuRide-008
Eikon Therapeutics
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
SUNRAY-01
Eli Lilly and Company
MK-3475-01A
Merck Sharp & Dohme LLC
KRAScendo 170
Hoffmann-La Roche
SOHO-02
Bayer
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Nanjing Leads Biolabs Co.,Ltd
MountainTAP-29
Bristol-Myers Squibb
INTerpath-009
Merck Sharp & Dohme LLC
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
TROPION-Lung15
AstraZeneca
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
eVOLVE-01
AstraZeneca
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines, Inc.
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Krascendo 2
Hoffmann-La Roche
PALOMA-2
Janssen Research & Development, LLC
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
HARMONIC
Lantern Pharma Inc.
ALTAIR
AstraZeneca
eVOLVE-Meso
AstraZeneca
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
DL03
AstraZeneca
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Amgen
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
SYNERGY-101
Synthekine
VELOCITY-Lung
Gilead Sciences
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
D3 Bio (Wuxi) Co., Ltd